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Suppressed injury-induced rise in spinal prostaglandin E2
production and reduced early thermal hyperalgesia in
iNOS-deficient mice
Abstract
It is widely accepted that peripheral injury increases spinal inducible cyclooxygenase (COX-2)
expression and prostaglandin E(2) (PGE(2)) formation as key mediators of nociceptive sensitization.
Here, we used inducible nitric oxide synthase (iNOS) gene-deficient (iNOS-/-) mice to determine the
contribution of iNOS-derived nitric oxide (NO) to this process. iNOS-/- mice exhibited reduced thermal
hyperalgesia after zymosan injection. Spinal NO and PGE(2) formation both remained at baseline
levels, in contrast to wild-type (wt) mice. In wt mice reduced hyperalgesia similar to that seen in
iNOS-/- mice was induced by local spinal, but not by systemic treatment with the iNOS inhibitor l-NIL,
suggesting that the reduced heat sensitization in iNOS-/- mice was attributable to the lack of spinal
rather than peripheral iNOS. Two additional observations indicate that the antinociceptive effects of
iNOS inhibition are dependent on a loss of stimulation of PG synthesis. First, intrathecal injection of the
COX inhibitor indomethacin, which exerted pronounced antinociceptive effects in wt mice, was
completely ineffective in iNOS-/- mice. Second, treatment with the NO donor RE-2047 not only
completely restored spinal PG production and thermal sensitization in iNOS-/- mice but also its
sensitivity to indomethacin. In both types of mice induction of thermal hyperalgesia was accompanied
by similar increases in COX-1 and COX-2 mRNA expression. The stimulation of PG production by NO
therefore involves an increase in enzymatic activity, rather than an alteration of COX gene expression.
These results indicate that NO derived from spinal iNOS acts as a fast inductor of spinal thermal
hyperalgesia.
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It is widely accepted that peripheral injury increases spinal in-
ducible cyclooxygenase (COX-2) expression and prostaglandin
E2 (PGE2) formation as key mediators of nociceptive sensitiza-
tion. Here, we used inducible nitric oxide synthase (iNOS) gene-
deficient (iNOS2/2) mice to determine the contribution of iNOS-
derived nitric oxide (NO) to this process. iNOS2/2 mice
exhibited reduced thermal hyperalgesia after zymosan injection.
Spinal NO and PGE2 formation both remained at baseline levels,
in contrast to wild-type (wt) mice. In wt mice reduced hyperal-
gesia similar to that seen in iNOS2/2 mice was induced by local
spinal, but not by systemic treatment with the iNOS inhibitor
L-NIL, suggesting that the reduced heat sensitization in
iNOS2/2 mice was attributable to the lack of spinal rather than
peripheral iNOS. Two additional observations indicate that the
antinociceptive effects of iNOS inhibition are dependent on a loss
of stimulation of PG synthesis. First, intrathecal injection of the
COX inhibitor indomethacin, which exerted pronounced antino-
ciceptive effects in wt mice, was completely ineffective in
iNOS2/2 mice. Second, treatment with the NO donor RE-2047
not only completely restored spinal PG production and thermal
sensitization in iNOS2/2 mice but also its sensitivity to indo-
methacin. In both types of mice induction of thermal hyperalge-
sia was accompanied by similar increases in COX-1 and COX-2
mRNA expression. The stimulation of PG production by NO
therefore involves an increase in enzymatic activity, rather than
an alteration of COX gene expression. These results indicate that
NO derived from spinal iNOS acts as a fast inductor of spinal
thermal hyperalgesia.
Key words: nitric oxide; inducible nitric oxide synthase; zymo-
san; thermal hyperalgesia; paw edema; spinal microdialysis; L-
NIL; RE-2047; prostaglandins; cyclooxygenase
Acute tissue damage is often accompanied by the fast development
of hyperalgesia and allodynia (Andrew and Greenspan, 1999). Both
peripheral mechanisms at the site of injury and central processes
particularly in the spinal cord contribute to this phenomenon.
Prostaglandins (PGs) (Yaksh and Malmberg, 1993; Brune, 1994) as
well as nitric oxide (NO) (Lawand et al., 1997) are produced in
response to tissue damage peripherally and centrally. Whereas PGs
are generally accepted to play a dominant role in nociceptive
sensitization (Bley et al., 1998), the role of NO is less clear. Also
some authors claim of an anti-nociceptive action of NO (Goettl and
Larson, 1996; Hamalainen and Lovick, 1997), most favor a pro-
nociceptive activity (Malmberg and Yaksh, 1993; Kawabata et al.,
1994; Chen and Levine, 1999). Part of this controversy may arise
from the existence of three different isoenzymes of NO synthase
(NOS) (Gonzalez-Hernandez and Rustioni, 1999), which may have
distinct effects on nociception, and from the lack of specific inhib-
itors for these different isoforms. In the CNS including the spinal
cord, NO is thought to be primarily produced by the neuronal
isoform of NOS (nNOS) (Downen et al., 1999). However, endo-
thelial NOS is also found in neurons (Wei et al., 1999) and under
certain conditions, e.g., after tissue damage (Sinz et al., 1999),
inducible NOS (iNOS) can be expressed in the CNS (Meller et al.,
1994; Lee and Brosnan, 1996; Barker et al., 1998). Therefore, all
three NO-generating isoenzymes appear to be possible sources of
NO in the CNS.
To define the role of NO in spinal processing of nociceptive
information more clearly, we investigated nociceptive sensitization
in genetically modified mice deficient in the iNOS isoenzyme
(iNOS2/2 mice). For this purpose, we adapted the Hargreaves
model of thermal hyperalgesia (Hargreaves et al., 1988) to mice
and developed a technique for spinal microdialysis in mice. We
showed that iNOS2/2 mice exhibit a delay in thermal sensitization
and lack the rise in spinal PG production, which is normally
observed in response to peripheral nociceptive stimulation.
MATERIALS AND METHODS
Assessment of thermal hyperalgesia. A modified Hargreaves plantar test
(Hargreaves et al., 1988) was used to assess thermal hyperalgesia in mice.
A metal grid bottom instead of a glass floor in the observation cage and
10.5 3 13.0 3 4.5 cm boxes to restrict animal movement were used.
Zymosan A (Sigma, Deisenhofen, Germany) was injected subcutaneously
into the plantar side of right hindpaws, and paw withdrawal latencies
(PWL) were determined on exposure of the paws to a defined thermal
stimulus were measured using a commercially available apparatus (Har-
greaves Test Ugo Basile Biological Research Apparatus, Comerio, Italy).
Mice were kept in the test cages for 1 d to allow accommodation. On day
2, each mouse was tested several times to gain baseline PWL. On day 3
thermal hyperalgesia was assessed for 8 hr starting 15 min after subcuta-
neous zymosan injection (3.0 mg/ml in 20 ml of PBS, containing NaCl 8
gm/l, Na2HPO4 2.9 gm/l, KCl 0.2 gm/l, KH2 PO4 0.24 gm/l). Experiments
were performed in air conditioned rooms (22°C) between 12 A.M. and 8
P.M. In some experiments the assessment of thermal hyperalgesia was
continued for 7 d (one measurement per day). Right (injected) and left
(noninjected) paws were measured alternately in intervals of 5–10 min. At
1 hr intervals, PWL were averaged.
Under control conditions, PWL were identical in wt (10.40 6 0.35 sec;
n 5 40) and iNOS2/2mice (10.25 6 0.20 sec; n 5 18). In an initial set of
experiments, zymosan (20 ml) was tested in concentrations of 12.0, 6.0, or
3.0 mg/ml. Zymosan injection caused a dose-dependent increase in areas
[PWL 3 observation interval [seconds 3 hours]; calculated using the
linear trapezoidal rule for each mouse] between right and left hindpaw
PWL from 0.17 6 1.75 (PBS) to 10.10 6 1.81 (3.0 mg/ml) to 17.47 6 2.55
(6.0 mg/ml) and to 23.30 6 2.22 (12.0 mg/ml). Injection of vehicle did not
affect nociceptive behavior in any of the experiments. For all subsequent
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tests an intermediate zymosan concentration of 3.0 mg/ml was used for the
detection of pro-nociceptive and anti-nociceptive effects.
Animals. Male iNOS2/2 mice weighing 26.7 (22.9–36.8) gm [mean
(range)] with the genetic background of C57/Bl6 mice and male C57/Bl6
mice (wt) weighing 21.2 (19.6–26.1) gm were used for all experiments.
Breeding pairs of iNOS 2/2 mice (Laubach et al., 1995) were obtained
from The Jackson Laboratory (Bar Harbor, ME). INOS 2/2 mice show
no major abnormalities (Laubach et al., 1995; MacMicking et al., 1995; Wei
et al., 1995). Mice were housed under a 12 hr light /dark cycle and cared for
according to the guidelines of the Institutional Animal Care and Use
Committee. Water and food were given ad libitum.
Application of drugs. All drugs were dissolved in isotonic, physiological
solvents. Indomethacin was dissolved as described elsewhere (Shen and
Winter, 1977). Briefly, for a 10 mM solution, 17.9 mg of indomethacin, 15.3
mg of Na2CO3 3 10 H2O, and 5 ml of artificial CSF (ACSF) consisting of
(in mM): 151.1 Na 1, 2.6 K 1, 0.9 Mg 21, 1.3 Ca 21, 122.7 Cl 2, 21.0 mM
HCO3 2, 2.5 mM HPO4 2, and 3.5 dextrose, pH 7.20, was used. Intraperi-
toneal drug or vehicle (PBS) injections (50 ml) were given into the lower
left abdominal quadrant. Intrathecal injections were performed according
to Hylden and Wilcox (1980). In brief, mice were anesthetized with
isoflurane, and 5 ml of drug containing solutions or vehicle (ACSF) were
injected into the spinal subarachnoid space between L5 and L6 30 min
before the administration of zymosan using a 26 gauge needle mated to a
10 ml Hamilton syringe. Mice showing neurological abnormalities were
excluded. We added 1% black ink (Pelikan, Hannover, Germany) to all
solutions used for intrathecal injections. Proper intrathecal injections were
verified by inspection of slices of the spinal cord after lumbar laminectomy.
Tissue samples. After completion of the Hargreaves test, mice were
killed under CO2 anesthesia by intracardial puncture and decapitation.
Hindpaws and the thoracolumbar segment of the spinal cord were removed
for morphological and biochemical analyses. After intra-articular discon-
nection at the ankle joint, right and left hindpaws were weighed. Differ-
ences in paw weight (D PW) were used to measure edema formation.
Spinal microdialysis. The dialysis tube was constructed from a Cu-
prophan hollow fiber (outer diameter, 216 mm) with a 36 kDa molecular
weight cutoff (Hospal, Nuernberg, Germany). This fiber was connected at
one side to a polyethylene (PE) tube (inner diameter, 0.4 mm; outer
diameter, 0.8 mm) using cyanacrylate glue (number 448 Stabiloplast;
Renfert, Chemietechnik, GmbH). A small metal spike was inserted into
the other side and fixed with a quick-setting cyanacrylate glue (UHU,
Buehl, Germany).
Mice were deeply anesthetized with isoflurane (1.5–2.0% vol; Abbott
GmbH, Wiesbaden, Germany) and placed on an electronically controlled
heating pad (37°C; CMA/Microdialysis, Stockholm, Sweden). After cuta-
neous incision of the thoracolumbar region, superficial and deep dorsal
lumbar fascia were slit, and muscle tissue was removed from the vertebrae
T12–L1. The dialysis tube was introduced through the intervertebral joints
between the thoracic and lumbar segments. All accessible parts of the
dialysis tube were covered with cyanacrylate glue. After cutting the spike,
the free end of the hollow fiber was connected to another PE tube using the
same cyanacrylate adhesive. Afterward mice were surgically sewed and
permanently anesthetized with urethane (;750 mg/kg, i.p.).
The PE tube was connected to a microdialysis pump (CMA 100; CMA/
Microdialysis), and ACSF was perfused at a flow rate of 3 ml /min. ACSF
was bubbled with carbogen (5% CO2 and 95% O2) and kept at 37°C during
the experiments. Samples were collected at 30 min intervals in Eppendorf
cups kept on ice and finally stored at 270°C for subsequent analysis of
PGE2, as well as NO2
2 and NO3
2 (NOx) as the breakdown products of
NO. After a washout period of 30 min, baseline samples were collected for
1.5 hr every 30 min. Thereafter, 20 ml of zymosan (3.0 mg/ml) was injected
subcutaneously into the right hindpaw, and samples were collected for
another 4 hr. After mice were killed, the proper placement of microdialysis
tubes was verified by perfusion with black ink (Pelikan), and subsequent
microscopic examination.
NOx and PGE2 measurements. NO production was assessed indirectly by
determining NO degradation products after reduction of NO3
2 to NO2
2
with nitrate reductase (Cytochrome; Sigma) by the Griess reaction-
dependent method described elsewhere (Green et al., 1981). We incubated
50 ml of perfusion samples with 50 ml of modified Griess reagent (Sigma),
and the absorption was recorded at 540 nm (Flow Titertec, Multiscan Plus
MK11; ICN Biochemicals, Frankfurt, Germany).
Tissue samples obtained from the spinal cord and from the hindpaws
were weighed, transferred into 99.5% methanol (1 mg of tissue to 10 ml of
methanol), and shaken for 2 hr at room temperature. We transferred 100
ml of the supernatants into Eppendorf cups, and methanol was evaporated.
The remaining pellet was dissolved in 100 ml of enzyme immunoassay
(EIA) buffer. We incubated 20 ml of the microdialysis perfusion samples
with 80 ml of enzyme immunoassay (EIA) buffer for PGE2 measurements.
All further steps were performed as described in the Cayman Chemical
Company PGE2 EIA Kit - Monoclonal, calibration range: 1000–7.8 pg/ml
(Cayman Chemicals, Ann Arbor, MI). Measurement was completed by
using an ELISA reader (Flow Titertec, Multiscan Plus MK11; ICN Bio-
chemicals) with an absorbency maximum at 405 nm.
RT-PCR. Immediately after preparation, tissue samples of the right
hindpaw and spinal cord segment L4 were snap frozen with 800 ml of lysis
buffer (Qiagen, Hilden, Germany) in liquid nitrogen, stored at 270°C, and
homogenized with a microshredder. RNA was isolated using the RNeasy-
kit (Qiagen). Real-time RT-PCR was used to determine expression of
mouse-actin, COX-1, and COX-2 mRNA. TaqMan probes were labeled at
the 59 end with the reporter dye molecule FAM (6-carboxy-fluorescein;
emission l, 518 nm), and at the 39 end with the quencher dye molecule
TAMRA (6-carboxy-tetramethyl-rhodamine, emission l, 582 nm). In ad-
dition, the 39 end was phosphorylated to prevent extension of the probe
during PCR.
We used 25 ml of reaction mixture, which contained 2 ml of template, 5
ml of 10 3 PCR buffer (100 mM Tris, pH 8.3, 500 mM KCl), 3 ml of
Mn(OAc)2, 0.3 ml of dATP, dCTP, dGTP, and dUTP, 0.1 ml of Diagonal
DNA polymerase, 0.05 ml of each primer, 0.05 ml of the TaqMan probe,
and 14.55 ml of sterile water for the PCR. For RT-PCR and detection of
fluorescence signals the ABI Prism 7700 SDS analytical thermal cycler
(Perkin-Elmer, Foster City, CA) was used. Thermal cycle conditions were:
2 min at 50°C, 30 min 60°C, 5 min 95°C, and then 45 cycles (15 sec at 94°C,
1 min at 60°C).
The emission of the reporter dye was compared with that of the quench-
ing dye during PCR amplification and the increase of fluorescence signals,
DRn, was calculated as: DRn 5 (Rn 1) 2 (Rn 2) [Rn 1 5 ratio of reporter
and quencher dye at any given time during a reaction; Rn 2 5 ratio of
reporter and quencher baseline emission]. Referring to a standard RNA a
threshold was defined indicating the exponential phase of the fluorescent
signal increase. The CT value, which correlates to the number of RNA
copies present at the start of PCR according to the references of PE
Applied Biosystems (User Bulletin 2; ABI PRISM 7700 Sequence Detec-
tion System, 1997) was determined as the amplification cycle number when
the DRn of a sample intersected this threshold value. The quantity of
mRNA was given as DCT, which was calculated as DCT 5 CT
gene of interest
2 CT
b -actin mRNA.
iNOS mRNA transcripts were analyzed in spinal cord tissue (thoraco-
lumbar segment) homogenates according to a protocol previously de-
scribed in detail (Deckert-Schluter et al., 1995). Primer sequences were
described previously (Deckert-Schluter et al., 1998; compare Table 1) and
were synthesized by TIB MOLBIOL (Berlin, Germany). Briefly, total
mRNA was extracted as described above. After reverse transcription of
mRNA using the Superscript RT kit (Life Technologies, Frederick, MD)
PCR reactions were conducted in a final volume of 25 ml of using the
AmpliTaq Gold kit from PE Biosystems (Weiterstadt, Germany). Condi-
tions are: 1 3 2 min 95°C; 45 3 1 min 95°C, 1 min 58°C, 1 min 72°C; 1 3
7 min 72°C. The PCR product was visualized by electrophoresis on 1.5%
agarose gels.
Statistical analysis. Results are expressed as the mean 6 SEM. The
statistical analyses of the behavioral experiments were performed using
one-way ANOVA followed by post hoc Bonferroni test (the a level was set
to 0.05) or by a Student’s t test ( p , 0.05 was considered statistically
significant).
Table 1. Primer sequences
b-actin forward -TCACCCACACTGTGCCCATCTACGA
b-actin reverse -GGATGCCACAGGATTCCATACCCA
b-actin probe -(6FAM)TATGCTC(TAMRA)TCCCTCACGCCATCCTGCGT
COX-2 forward -TTTGTTGAGTCATTCACCAGACAGAT
COX-2 reverse -CAGTATTGAGGAGAACAGATGGGATT
COX-2 probe -(6FAM)CTACCATGGTC(TAMRA)TCCCCAAAGATAGCATCA
iNOS forward -TCACGCTTGGGTCTTGTTCACT
iNOS reverse -TTGTCTCTGGGTCCTCTGGTCA
Forward and reverse primer as well as probe sequences for real time RT-PCR of b-actin and COX-2. Forward and reverse
primer sequences for RT-PCR of iNOS.
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RESULTS
iNOS-derived NO facilitates development of
spinal hyperalgesia
A modification of the Hargreaves test was used to assess thermal
hyperalgesia in wt and iNOS2/2 mice. Both types of mice exhib-
ited a time-dependent sensitization to noxious heat in response to
plantar zymosan injection. At the time point of maximum thermal
hyperalgesia, PWL were reduced from ;10 sec under control
conditions to ;3 sec after zymosan injection. In wt mice, however,
maximum sensitization occurred after 3 hr, whereas that of
iNOS2/2 mice was not reached until 8 hr (Fig. 1). Wild type-like
thermal sensitization could be restored in iNOS2/2 mice by treat-
ment with the NO-donor RE-2047 (3-methyl-N-nitroso-sydnone-5-
imine; a generous gift from Prof. Rehse, Department of Pharma-
ceutical Chemistry, Berlin, Germany) (Rehse and Ciborski, 1995)
in a dose-dependent manner. At the highest dose of RE-2047
hyperalgesia in iNOS2/2 mice was indistinguishable from that of
wt mice, confirming that the reduced thermal sensitization in
iNOS2/2 mice was caused by the absence of NO generated by
iNOS (Fig. 2).
To determine whether the lack of iNOS in the peripheral tissue
or in the CNS was responsible for reduced early thermal hyperal-
gesia, we used the selective iNOS inhibitor L-NIL (L-N6-(I-
iminoethyl)-lysine hydrochloride; Alexis Biochemicals, Gruenberg,
Germany; Moore et al., 1994) and took advantage of its inability to
penetrate the blood–brain barrier in significant amounts (U.
Werner, B. Layh, K. Brune, H. and Guehring, unpublished obser-
vations). In this series of experiments we compared the effects of
L-NIL after systemic peripheral (intraperitoneal) and local spinal
(intrathecal) injection in wt mice. After intraperitoneal injection at
doses ranging from 15.0 to 135.0 mg/kg L-NIL effectively reduced
edema and PGE2 production in the zymosan-injected paw, but had
no effect on thermal hyperalgesia (Fig. 3A, Table 2). Increases in
the weight of the injected paws were 35.2 6 3.0% and 48.7 6 2.1%
in L-NIL and vehicle-treated mice, respectively. A similar differ-
ence was found for the PGE2 content in the zymosan-injected
paws, which was 25.6 6 5.0 pg/mg in L-NIL treated and 54.6 6 2.7
pg/mg in control mice. As expected, L-NIL was completely inef-
fective in iNOS2/2 mice. Both paw edema formation and PGE2
production in L-NIL-treated mice were not significantly different
from those found in iNOS2/2 mice (edema, 30.25 6 4.14%; PGE2,
23.3 6 1.9 pg/mg).
By contrast, when L-NIL (0.1 mM; 5 ml) was injected intrathecally
the development of zymosan-induced sensitization was signifi-
cantly retarded compared to vehicle (ACSF; 5 ml)-treated animals
and indistinguishable from that of iNOS2/2 mice (Fig. 3B). The
latter finding indicates that the lack of spinal rather than of periph-
eral iNOS was responsible for the observed delay in thermal hy-
peralgesia. Interestingly, neither L-NIL nor the nonspecific NOS
inhibitor L-NAME (NG-nitro-L-arginine methyl ester; Alexis Bio-
chemicals, Gruenberg, Germany; Amir and English, 1991) affected
heat sensitization in iNOS2/2 mice (Table 3), indicating that
nNOS and eNOS did not significantly contribute to zymosan-
induced thermal hyperalgesia.
To investigate whether the facilitating action of iNOS on thermal
hyperalgesia was related to the COX system in the spinal cord, we
compared the effects of spinal COX inhibition in iNOS2/2 and wt
mice. In wt mice intrathecal injection of the COX inhibitor indo-
methacin (Sigma) reduced thermal hyperalgesia in a dose-
dependent manner (Fig. 4A). This antinociceptive effect was com-
pletely absent in iNOS2/2 mice (Table 3, Fig. 4B) but was restored
after substitution of NO with RE-2047, suggesting that the increase
in spinal PGE2 production after zymosan injection required NO,
which in wt mice is produced by spinal iNOS.
Spinal NOx and PGE2 formation
The difference in heat sensitization between wt and iNOS2/2
mice was already present 1 hr after zymosan injection. Because
iNOS is generally considered not to be constitutively expressed in
the CNS, the fast rise in NO production after zymosan injection
would require an at least equally fast induction of iNOS expression.
We have therefore analyzed the expression of iNOS mRNA during
the early phase of hyperalgesia development by RT-PCR (Fig. 5).
Significant amounts of iNOS mRNA were detected 30 and 60 min
after zymosan injection and 120 min after zymosan injection in
separate experiments (data not shown). As expected, iNOS mRNA
was absent under control conditions and in iNOS2/2 mice after
zymosan injection.
To further elucidate the role of iNOS in the spinal mechanisms
of heat sensitization and its relation to the COX pathway we
performed spinal microdialysis to measure NO and PGE2 produc-
tion in the spinal cord in response to zymosan injection. In a first
series of experiments we tested whether insertion of the microdi-
alysis probe was sufficient to induce spinal PG formation. In these
experiments, PBS instead of zymosan was injected subcutaneously
into the right hindpaw. Under these conditions only a modest
increase in PGE2 was induced in wt mice (from 18.4 6 1.9 to 26.3 6
2.5 pg/ml).
Figure 1. Time course of zymosan-induced thermal hyperalgesia in
iNOS2/2 mice. Development with time of PWL in iNOS2/2 (n 5 12;
open circles) and wt mice (n 5 12; black circles) after intraperitoneal
administration of PBS and after injection of 3.0 mg/ml zymosan subcuta-
neously into the right hindpaw. Left PWLs (black lines) were similar for
both lines of mice. Different PWL (*p , 0.05) indicate reduced heat
sensitization after zymosan injection in iNOS2/2 mice. Data are expressed
as means 6 SEM.
Figure 2. NO donor restores thermal hyperalgesia in iNOS2/2 mice.
Intraperitoneal injection of RE-2047, a metabolic NO-donor, in doses
increasing from 5 (black diamonds) to 15 ( gray diamonds) and 45 mg/kg
(open diamonds) antagonized the restored heat sensitization of iNOS2/2
mice. The difference of heat sensitization between wt (black circles) and
iNOS2/2 mice (open circles) after intraperitoneal administration of PBS is
drawn as dotted lines.
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When zymosan was injected, both PGE2 and NO degradation
products (NOx,, i.e., NO2
2 and NO3
2) increased in wt mice. NOx
concentrations reached their maximum already after 1 hr and thus
closely paralleled the development of iNOS-dependent hyperalge-
sia (Fig. 6A). By contrast, PGE2 showed a more prolonged in-
crease, exhibiting a continuous rise over the whole observation
period of 4 hr (Fig. 6B).
Next we investigated whether the effects of reduced NO forma-
tion on nociceptive sensitization might be secondary to a suppres-
sion of PGE2 formation. iNOS2/2 mice lacked not only the
zymosan-induced increase in NO, but also showed reduced spinal
PGE2 formation. The rise in PGE2 production was much smaller
compared to that in wt mice. As described above the NO donor
RE-2047 reconstituted wt-like hyperalgesia in iNOS2/2 mice. As
shown in Figure 6A, RE-2047 not only increased spinal NOx
concentrations, but also restored spinal PGE2 formation (Fig. 6B).
We analyzed whether the expression of COX-1 or COX-2 differs
in iNOS2/2 and wt mice. Time course of COX-1 and COX-2
mRNA expression and of the PGE2 concentration in spinal cord
tissue was followed for 7 d. As shown in Figure 7A, increases in
PGE2 concentrations reached their maximum 8 hr after zymosan
injection, declined, and came back to baseline levels after 7 d. In
iNOS 2/2 mice the rise in PGE2 was again largely suppressed, and
only at 8 hr a modest increase in PGE2 was seen.
In contrast to the striking difference in PGE2 production seen
between iNOS2/2 and wt mice, COX-1 and COX-2 mRNA
expression were very similar in both types of mice. This suggests
that the NO-induced rise in PGE2 levels was attributable to an
increase in COX-1 and/or COX-2 enzymatic activity, rather than
to altered gene expression.
DISCUSSION
Our data indicate that NO production from iNOS in the spinal cord
immediately follows the early induction of peripheral tissue dam-
age and inflammation. This process occurs in parallel to the devel-
opment of thermal hyperalgesia and is required for the increase in
spinal PGE2 production. Our data therefore attribute a decisive
role to iNOS in the early phase of development of thermal
hyperalgesia.
It appears that NO production immediately after peripheral
Figure 3. Effects of peripheral versus spinal injection of L-NIL on thermal
hyperalgesia in wt mice. A, In wt mice (open diamonds) the selective iNOS
inhibitor L-NIL administered intraperitoneally was without any effect even
in doses ranging from 5 to 135 mg/kg. The difference of heat sensitization
between wt (black circles) and iNOS2/2 mice (open circles) after intraperi-
toneal administration of PBS is drawn as dotted lines. Data are expressed as
mean 6 SEM. B, In contrast to A drugs were administered intrathecally.
Intrathecal administration of L-NIL (0.1 mM) to wt mice (black diamonds)
reduced heat sensitization significantly to the level of iNOS2/2 mice.
Differences in heat sensitization between wt (black circles) and iNOS2/2
mice (open circles) were also observed after acute intrathecal injection of
ACSF (5 ml). Data are expressed as means 6 SEM.
Table 2. Thermal hyperalgesia after intraperitoneal administration of
drugs
Mouse
Drug mg/kg
(i.p.)
Hindpaw
stimulus
Area
(0–8 hr)
Area
(8–168 hr)
wt PBS Zymosan 63.0 6 2.03 593.7 6 56.20
iNOS 2/2 PBS Zymosan 40.8 6 2.89 586.1 6 132.21
wt L-NIL 15 Zymosan 60.5 6 2.53
wt L-NIL 45 Zymosan 67.6 6 4.10
wt L-NIL 135 Zymosan 65.5 6 3.01
wt Diclofenac 5 Zymosan 34.8 6 1.32
iNOS 2/2 RE 5 Zymosan 47.3 6 1.66
iNOS 2/2 RE 15 Zymosan 54.7 6 0.84
iNOS 2/2 RE 45 Zymosan 60.7 6 0.83
wt PBS PBS 5.0 6 1.12
iNOS 2/2 PBS PBS 3.0 6 2.50
Areas [sec*hr] between right and left hindpaws calculated from PWL in two different
time intervals from 0 to 8 hr and from 8 to 168 hr in wt (wt) and iNOS-gene deficient
(iNOS2/2) mice. Peripheral inflammation was induced with zymosan, and PBS was
used as a control. Data are expressed as means 6 SEM.
Table 3. Thermal hyperalgesia after intrathecal administration of drugs
Mouse Drug (i.t.) Area (0–8 hr)
wt ACSF 62.0 6 1.52
iNOS 2/2 ACSF 45.1 6 1.26
wt L-NIL 0.1 mM 42.1 6 0.57
iNOS 2/2 L-NIL 0.1 mM 43.0 6 2.96
iNOS 2/2 L-NAME 0.1 mM 39.5 6 1.27
wt Indo 0.1 mM 60.4 6 2.22
wt Indo 1.0 mM 56.4 6 2.96
wt Indo 10.0 mM 46.3 6 3.64
iNOS 2/2 Indo 0.1 mM 42.4 6 0.88
iNOS 2/2 Indo 1.0 mM 42.1 6 1.58
iNOS 2/2 Indo 10.0 mM 42.8 6 1.17
iNOS 2/2 RE 45 mg/kg, i.p.
Indo 10.0 mM, i.t.
41.5 6 2.44
Areas [sec*hr] between right and left hindpaws calculated from PWL in the time
interval from 0 to 8 hr in wt (wt) and iNOS-gene deficient (iNOS2/2) mice. In every
mouse peripheral inflammation was induced with zymosan. Indo, Indomethacin. Data
are expressed as means 6 SEM.
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tissue damage is predominantly iNOS-derived. This is corrobo-
rated by our results, which show an induction of iNOS mRNA in
the spinal cord as early as 30 min after zymosan injection. Further-
more, administration of L-NAME intrathecally into iNOS2/2
mice was without any effect with regard to thermal hyperalgesia.
This strongly argues against an extensive contribution of nNOS or
eNOS. Observations of Clark et al. (1996), MacNaughton et al.
(1998), Haddad et al. (1995), and Salvemini et al. (1995) of an early
iNOS expression also support our results. Reconstitution of the fast
development of hyperalgesia by the NO donor RE-2047 (Rehse
and Ciborski, 1995) demonstrates the importance of early NO
production. To relate this to the lack of iNOS genes, we injected the
selective iNOS inhibitor L-NIL into wt mice; it reduced develop-
ment of thermal hyperalgesia. The dose of L-NIL chosen (0.1 mM;
5 ml) does not affect the other NOS isoforms (Moore et al., 1994).
Furthermore, our results support previous studies showing that
selective pharmacological inhibition of iNOS attenuates thermal
hyperalgesia in rats (Osborne and Coderre, 1999). Only when given
intrathecally did L-NIL inhibit NO production in the spinal cord
and result in antinociceptive effects. These data indicate that only
spinal iNOS-derived NO production correlates with antinocicep-
tive activity. Interestingly, a substantial part of thermal hyperalge-
sia was insensitive to inhibition of iNOS and is also considered
insensitive to COX inhibition. This insensitivity becomes domi-
nant during the late phase of thermal sensitization ;8 hr after
zymosan injection. It is likely that both peripheral mechanisms
such as sensitization of capsaicin receptors (Caterina et al., 1997;
Kress and Zeilhofer, 1999) and central mechanisms independent
from PG and NO contribute to this late phase.
In wt mice, COX inhibition by indomethacin and disruption of
the iNOS gene resulted in virtually indistinguishable antinocicep-
tive effects. In iNOS2/2 mice, indomethacin failed to display an
antinociceptive effect. Antinociceptive activity could be restored in
these mice by adding back NO with the NO donor RE-2047. These
results demonstrate that the production of spinal PGE2 requires
spinal NO and that spinal iNOS-derived NO appears to mediate
thermal hyperalgesia largely if not solely via an increase in spinal
PGE2 formation. In this respect, our data support previous evi-
dence that PGs are key mediators of thermal hyperalgesia (Minami
et al., 1994; Ferreira and Lorenzetti, 1996; Yamamoto and Nozaki-
Taguchi, 1997). We also confirmed findings that hindpaw inflam-
mation produces enhanced PG levels in the spinal cord (Yang et
al., 1996; Hay and de Belleroche, 1997; Ichitani et al., 1997;
Yamamoto and Nozaki-Taguchi, 1997; Dirig and Yaksh, 1999;
Ebersberger et al., 1999).
In line with several studies, we could show that PG production in
the spinal cord is modulated positively by NO release and is
diminished by lack of NO production (Salvemini et al., 1994, 1995;
Salvemini, 1997; but see also Hamilton and Warner, 1998). Substi-
tution of NO by RE-2047 completely reconstituted PGE2 produc-
tion in iNOS2/2 mice as well as nociceptive responses in the
behavioral tests, indicating once again that iNOS-derived NO am-
plifies PG production at spinal level. Moreover, the constitutive
baseline mRNA expression (Beiche et al., 1996, 1998) and
zymosan-induced expression of COX-2 were similar in both types
of mice in the dorsal horn of the spinal cord. Consequently, it
appears plausible to attribute to iNOS-derived NO a pivotal role as
a trigger of spinal enzymatic PG production.
Figure 4. Effects of indomethacin in wt and iNOS2/2 mice. A, Intrathecal
injection of indomethacin, a nonselective COX inhibitor, in ascending
doses of 0.1 (black diamonds) to 1.0 ( gray diamonds) and 10.0 mM (open
diamonds) decelerated the development of thermal hyperalgesia of wt mice.
Intrathecal injection was performed to exclude the possibility of a decreased
production of prostaglandins in the inflamed hindpaws during systemic
application of COX inhibitors. Wt (black circles) and iNOS2/2 mice (open
circles) after acute intrathecal injection of ACSF (5 ml). Data are expressed
as mean 6 SEM. B, Intrathecal injection of indomethacin 10.0 mM (black
triangle) antagonized the development of thermal hyperalgesia after intra-
peritoneal pretreatment with the NO donor RE-2047 (45 mg/kg).
iNOS2/2 mice after intraperitoneal pretreatment with 45 mg/kg RE-2047
and after intrathecal injection of ACSF (black diamonds) served as con-
trols. Thermal hyperalgesia in iNOS2/2 mice was not affected after intra-
peritoneal pretreatment with PBS and intrathecal pretreatment with indo-
methacin 10.0 mM (black triangle). Wt (black circles) and iNOS2/2 mice
(open circles) after acute intrathecal injection of 5 ml of ACSF (dotted lines).
Data are expressed as means 6 SEM.
Figure 5. Early iNOS mRNA expression in wt mice. iNOS mRNA expres-
sion in spinal cord of wt and iNOS2/2 mice after zymosan injection into
the right hindpaw. In wt but not in iNOS2/2 mice, iNOS mRNA was
increased in thoracolumbar segment of spinal cord even 0.5 (3 of 6 mice)
and 1 hr (6 of 6 mice) after peripheral inflammation. b-actin RT-PCR
product level served as control. This figure represents one of two indepen-
dent experiments.
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PGE2 and NO production did not run in parallel. NO exhibited
a fast peak within ;1 hr, whereas increases in PGE2 occurred at a
markedly prolonged time scale. Our results suggest that PGE2
production is not attributable to increased COX-1 or COX-2
expression. It may be speculated that the enhanced early PG
production is caused by a free radical driven modulation of phos-
pholipase A2 activity and therefore of the concentration of arachi-
donic acid, which is the rate-limiting substrate of PG production
(but see also Zingarelli et al., 1997; Sahnoun et al., 1998). However,
a direct or indirect interaction of NO or one of its metabolites with
the COX-1 or COX-2 proteins by enhancing their enzymatic
activity is also possible (Salvemini, 1997). In either case one would
assume that the NO-induced change in COX enzyme activity
outlasts the rise in spinal NO, e.g., via sustained changes in enzyme
activity of COX-1, COX-2, or phospholipase A2.
An intriguing question raised by our study is whether inhibition
of iNOS provides a novel target for analgesic therapy. Our exper-
iments have shown that inhibition of iNOS via gene disruption or
by selective drugs almost completely abolishes the PG-mediated
part of thermal hyperalgesia. With the possible exception of inhi-
bition of resistance to certain microbial agents, iNOS2/2 mice are
not only viable but also show no major abnormalities indicating that
pharmacological inhibition of iNOS may be considered as largely
safe. The use of iNOS inhibitors as analgesics would be largely
limited by the fact that they would have to be administered very
early, before spinal PG production has been triggered.
Our data also indicate that NO donors reaching the CNS may be
enhancers of pain development and in this respect be problematic.
This observation is in line with findings of Urban et al. (1999),
Inoue et al. (1997), and Aley et al. (1998) (but see also Lauretti et
al., 1999) and should be subjected to further research.
Our data offer no clues indicating whether the decrease of NO
production seen in our animals before hyperalgesia reaches its peak
is of importance for the later normalization of hyperalgesia that
goes along with healing processes in the damaged tissue (Reichner
et al., 1999).
In summary, we have shown that NO generated by iNOS not only
plays an important role as a mediator of tissue inflammation acting
in peripheral tissue, but that it also serves an important role in the
spinal cord, where it triggers PGE2 formation, enhances COX-2
activity, and facilitates the development of thermal and possibly
other forms of hyperalgesia.
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